Leerink Partnrs Analysts Boost Earnings Estimates for APLT

Applied Therapeutics, Inc. (NASDAQ:APLT) – Equities researchers at Leerink Partnrs raised their Q2 2025 earnings per share estimates for shares of Applied Therapeutics in a research report issued on Tuesday, May 13th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.18) per share for the quarter, up from their prior estimate of ($0.24). The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Applied Therapeutics’ Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.65) EPS and FY2026 earnings at ($0.41) EPS.

Applied Therapeutics (NASDAQ:APLT) last announced its quarterly earnings data on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.61 million.

Separately, Royal Bank of Canada restated a “sector perform” rating and issued a $1.50 price target on shares of Applied Therapeutics in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Applied Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $6.10.

Applied Therapeutics Price Performance

APLT stock opened at $0.60 on Friday. Applied Therapeutics has a 1-year low of $0.30 and a 1-year high of $10.62. The company has a market capitalization of $85.36 million, a price-to-earnings ratio of -0.37 and a beta of 2.00. The business has a 50 day simple moving average of $0.43 and a two-hundred day simple moving average of $1.96.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in APLT. CreativeOne Wealth LLC raised its holdings in Applied Therapeutics by 132.2% during the 1st quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company’s stock valued at $25,000 after buying an additional 28,701 shares during the period. Ground Swell Capital LLC purchased a new stake in Applied Therapeutics during the 4th quarter valued at $27,000. Toronto Dominion Bank purchased a new stake in Applied Therapeutics during the 4th quarter valued at $27,000. Private Advisor Group LLC purchased a new stake in Applied Therapeutics during the 4th quarter valued at $35,000. Finally, SG Americas Securities LLC raised its holdings in Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after buying an additional 25,601 shares during the period. 98.31% of the stock is currently owned by institutional investors.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.